Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial.

Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial. Nature medicine Collet, C., Mahendiran, T., Fearon, W. F., Mizukami, T., Munhoz, D., Pijls, N. H., Tonino, P. A., Barbato, E., Piroth, Z., Sreckovic, M., Thiele, H., El Farissi, M., Witt, N., Rioufol, G., Kala, P., Engstrøm, T., Mavromatis, K., Fröbert, O., Verlee, P., Brunner, S., Mates, M., Jagic, N., Campo, G., Pardaens, S., Ikeda, K., Pereira, T. V., da Costa, B. R., Fournier, S., De Bruyne, B., Jüni, P. 2026

Abstract

In patients with stable coronary artery disease (CAD), the long-term benefits of revascularization over medical therapy remain unclear. In the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 trial, patients with hemodynamically significant stenoses (fractional flow reserve (FFR)?=?0.80) were randomized to receive FFR-guided percutaneous coronary intervention (PCI) plus medical therapy (n?=?447) or medical therapy alone (n?=?441). At 5?years, FFR-guided PCI reduced the risk of the primary composite outcome of time to death, myocardial infarction or urgent revascularization, largely because of fewer urgent revascularizations. We now report the long-term clinical outcomes from this trial. Sixteen hospitals, contributing 748 randomized patients (161 women, 21.5%), participated in the long-term follow-up. The primary composite outcome was analyzed hierarchically using the unstratified win ratio, which addressed differential missingness of data on nonfatal outcomes in deceased patients by prioritizing comparisons on time to death. At a median follow-up of 11.2?years, the primary endpoint occurred in 150 of 447 patients (33.6%) in the PCI group versus 182 of 441 (41.3%) in the medical therapy group. PCI was superior in 29.2% of comparisons, medical therapy in 23.3%, and the two groups were tied in 47.5%, resulting in a win ratio of 1.25 in favor of PCI (95% confidence interval (CI) 1.01-1.56, P?=?0.043). The corresponding win difference was 5.9% (95% CI 0.2-11.6), and the number needed to treat was 17 (95% CI 9-500). Win ratios were 0.88 for all-cause death (95% CI 0.66-1.17), 1.50 for myocardial infarction (95% CI 0.98-2.31) and 4.57 for urgent revascularization (95% CI 2.53-8.24). During long-term follow-up, FFR-guided PCI in patients with stable CAD and hemodynamically significant stenoses reduced the composite of death, myocardial infarction or urgent revascularization, primarily because of fewer urgent revascularizations. These long-term findings reaffirm the efficacy of FFR-guided PCI over medical therapy in patients with stable CAD. ClinicalTrials.gov registration: NCT06159231 .

View details for DOI 10.1038/s41591-025-04132-5

View details for PubMedID 41540107

View details for PubMedCentralID 7615400